Enhanced Stability and Oral Bioavailability of Cannabidiol in Zein and Whey Protein Composite Nanoparticles by a Modified Anti-Solvent Approach

Sun, Yonghai; Freeman, Kalev; McHenry, Monique A.; Wang, Cuina; Guo, Mingruo

doi:10.3390/foods11030376

Cited by 29 publications

(21 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The CBD extraction step was modified from the reference. [50][51][52] First, 20 µL 10M KOH was added to 100 µL serum and heated at 70 °C for 30 min, subsequently adding 5 µL formic acid left standing for 5 min. Next, 625 µL of ACN was added, mixed well, and ultrasonicated for 30 min, then centrifuged at 5000 G, 4 °C for 5 minutes.…”

Section: In Vivo Pharmacokinetic Evaluationmentioning

confidence: 99%

Key Transdermal Patch Using Cannabidiol-Loaded Nanocarriers with Better Pharmacokinetics in vivo

Chu,

Liao,

Liu

et al. 2024

IJN

View full text Add to dashboard Cite

Purpose: Cannabidiol (CBD) is a promising therapeutic drug with low addictive potential and a favorable safety profile. However, CBD did face certain challenges, including poor solubility in water and low oral bioavailability. To harness the potential of CBD by combining it with a transdermal drug delivery system (TDDS). This innovative approach sought to develop a transdermal patch dosage form with micellar vesicular nanocarriers to enhance the bioavailability of CBD, leading to improved therapeutic outcomes. Methods: A skin-penetrating micellar vesicular nanocarriers, prepared using nano emulsion method, cannabidiol loaded transdermal nanocarriers-12 (CTD-12) was presented with a small particle size, high encapsulation efficiency, and a drug-loaded ratio for CBD. The skin permeation ability used Strat-M™ membrane with a transdermal diffusion system to evaluate the CTD and patch of CTD-12 (PCTD-12) within 24 hrs. PCTD-12 was used in a preliminary pharmacokinetic study in rats to demonstrate the potential of the developed transdermal nanocarrier drug patch for future applications. Results: In the transdermal application of CTD-12, the relative bioavailability of the formulation was 3.68 ± 0.17-fold greater than in the free CBD application. Moreover, PCTD-12 indicated 2.46 ± 0.18-fold higher relative bioavailability comparing with free CBD patch in the ex vivo evaluation. Most importantly, in the pharmacokinetics of PCTD-12, the relative bioavailability of PCTD-12 was 9.47 ± 0.88-fold higher than in the oral application. Conclusion: CTD-12, a transdermal nanocarrier, represents a promising approach for CBD delivery, suggesting its potential as an effective transdermal dosage form.

show abstract

Section: In Vivo Pharmacokinetic Evaluationmentioning

confidence: 99%

Key Transdermal Patch Using Cannabidiol-Loaded Nanocarriers with Better Pharmacokinetics in vivo

Chu,

Liao,

Liu

et al. 2024

IJN

View full text Add to dashboard Cite

show abstract

“…For example, the storage stability of 7,8-dihydroxyflavone (7,8-DHF) was strengthened greatly after encapsulation in zein NPs, especially with the addition of glycosylated lactoferrin ( Chen et al, 2022 ). Similarly, zein NPs has been used to improving the storage stability of cannabidiol ( Wang et al, 2022a ), resveratrol ( Khan et al, 2021 ), curcumin ( Yuan et al, 2020 ) and others.…”

Section: Pharmaceutical Application Of Zein-based Nanoparticlesmentioning

confidence: 99%

Zein-based nanoparticles: Preparation, characterization, and pharmaceutical application

Liu

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Zein, as one of the natural and GRAS proteins in plant, is renewable, nontoxic, biocompatible and biodegradable. Over the past decade, many research efforts have been devoted to zein-based biomaterials for several industrial applications. Combining with research experiences in our research group, the preparation methods, characterizations and pharmaceutical applications of zein-based nanoparticles were summarized in this review. Zein NPs with different particle nanostructures have been prepared by chemical crosslinking, desolvating, dispersing and micromixing strategies. The pharmaceutical applications of zein NPs are mainly focus on the drug delivery. Zein NPs can improve the drug stability, increase the oral bioavailability, control the drug release and enhance the drug targeting, thereby improving the pharmaceutical effect effectively. More efforts are required to analyze the relationship among preparation methods, particle nanostructures and pharmaceutical properties in virtue of quality by design approach, and further promote the scale-up production and clinical application of zein NPs.

show abstract

“…tiredness, diarrhea, and changes in appetite) [173], the number and extent of adverse effects may increase with the dose. Various formulations have been investigated to improve the solubility of CBD, such as the use of cyclodextrins [174][175][176], mesoporous silica [174], polymers [142,174], self-emulsifying drug delivery systems [177][178][179][180], and other nanoformulations [181][182][183]. By increasing CBD solubility, oral bioavailability can be enhanced.…”

Section: Optimal Routes Of Administrationmentioning

confidence: 99%

Cannabidiol for the Treatment of Brain Disorders: Therapeutic Potential and Routes of Administration

et al. 2023

View full text Add to dashboard Cite

The use of cannabidiol (CBD) for treating brain disorders has gained increasing interest. While the mechanism of action of CBD in these conditions is still under investigation, CBD has been shown to affect numerous different drug targets in the brain that are involved in brain disorders. Here we review the preclinical and clinical evidence on the potential therapeutic use of CBD in treating various brain disorders. Moreover, we also examine various drug delivery approaches that have been applied to CBD. Due to the slow absorption and low bioavailability with the current oral CBD therapy, more efficient routes of administration to bypass hepatic metabolism, particularly pulmonary delivery, should be considered. Comparison of pharmacokinetic studies of different delivery routes highlight the advantages of intranasal and inhalation drug delivery over other routes of administration (oral, injection, sublingual, buccal, and transdermal) for treating brain disorders. These two routes of delivery, being non-invasive and able to achieve fast absorption and increase bioavailability, are attracting increasing interest for CBD applications, with more research and development expected in the near future.

show abstract

Enhanced Stability and Oral Bioavailability of Cannabidiol in Zein and Whey Protein Composite Nanoparticles by a Modified Anti-Solvent Approach

Cited by 29 publications

References 43 publications

Key Transdermal Patch Using Cannabidiol-Loaded Nanocarriers with Better Pharmacokinetics in vivo

Key Transdermal Patch Using Cannabidiol-Loaded Nanocarriers with Better Pharmacokinetics in vivo

Zein-based nanoparticles: Preparation, characterization, and pharmaceutical application

Cannabidiol for the Treatment of Brain Disorders: Therapeutic Potential and Routes of Administration

Contact Info

Product

Resources

About